Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 1;203(1):54-66.
doi: 10.1164/rccm.202006-2405OC.

Case Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical Ventilation. A Meta-analysis

Affiliations
Review

Case Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical Ventilation. A Meta-analysis

Zheng Jie Lim et al. Am J Respir Crit Care Med. .

Abstract

Rationale: Initial reports of case fatality rates (CFRs) among adults with coronavirus disease (COVID-19) receiving invasive mechanical ventilation (IMV) are highly variable.Objectives: To examine the CFR of patients with COVID-19 receiving IMV.Methods: Two authors independently searched PubMed, Embase, medRxiv, bioRxiv, the COVID-19 living systematic review, and national registry databases. The primary outcome was the "reported CFR" for patients with confirmed COVID-19 requiring IMV. "Definitive hospital CFR" for patients with outcomes at hospital discharge was also investigated. Finally, CFR was analyzed by patient age, geographic region, and study quality on the basis of the Newcastle-Ottawa Scale.Measurements and Results: Sixty-nine studies were included, describing 57,420 adult patients with COVID-19 who received IMV. Overall reported CFR was estimated as 45% (95% confidence interval [CI], 39-52%). Fifty-four of 69 studies stated whether hospital outcomes were available but provided a definitive hospital outcome on only 13,120 (22.8%) of the total IMV patient population. Among studies in which age-stratified CFR was available, pooled CFR estimates ranged from 47.9% (95% CI, 46.4-49.4%) in younger patients (age ≤40 yr) to 84.4% (95% CI, 83.3-85.4%) in older patients (age >80 yr). CFR was also higher in early COVID-19 epicenters. Overall heterogeneity is high (I2 >90%), with nonsignificant Egger's regression test suggesting no publication bias.Conclusions: Almost half of patients with COVID-19 receiving IMV died based on the reported CFR, but variable CFR reporting methods resulted in a wide range of CFRs between studies. The reported CFR was higher in older patients and in early pandemic epicenters, which may be influenced by limited ICU resources. Reporting of definitive outcomes on all patients would facilitate comparisons between studies.Systematic review registered with PROSPERO (CRD42020186997).

Keywords: COVID-19; SARS-CoV-2; case fatality rate; invasive mechanical ventilation; mortality.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart of study inclusions and exclusions. Adapted from Reference .
Figure 2.
Figure 2.
Forest plot of the reported case fatality rates (N = 69 studies) for patients receiving invasive mechanical ventilation stratified by continent. CFR = case fatality rate; CI = confidence interval; ICNARC = Intensive Care National Audit and Research Centre; REML = restricted maximum likelihood.
Figure 3.
Figure 3.
Reported case fatality rates for patients receiving invasive mechanical ventilation stratified by age, reported in six studies. *Age stratification for ICNARC was 16–39, 40–49, 50–59, 60–69, 70–79, and ≥80. CFR = case fatality rate; CI = confidence interval; Expon. = exponential; ICNARC = Intensive Care National Audit and Research Centre; IMV = invasive mechanical ventilation.

Comment in

References

    1. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020;395:1225–1228. - PMC - PubMed
    1. World Health Organization. Geneva, Switzerland: World Health Organization; 2020. Coronavirus disease (COVID-19) situation reports. [accessed 2020 Jul 30]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situatio....
    1. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9:727–732. - PMC - PubMed
    1. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. ACTT-1 Study Group Members. Remdesivir for the treatment of COVID-19: final report. N Engl J Med. [online ahead of print] 8 Oct 2020; DOI: 10.1056/NEJMoa2007764. - PMC - PubMed
    1. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19: preliminary report. N Engl J Med. [online ahead of print] 17 Jul 2020; DOI: 10.1056/NEJMoa2021436.